FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms.
about
Development and validation of a discriminative dissolution method for atorvastatin calcium tablets using in vivo data by LC and UV methodsFast dissolving strips: A novel approach for the delivery of verapamil.Development and validation of a discriminative dissolution test for betamethasone sodium phosphate and betamethasone dipropionate intramuscular injectable suspension.Dissolution testing for generic drugs: an FDA perspective.QbD-based carbopol transgel formulation: characterization, pharmacokinetic assessment and therapeutic efficacy in diabetes.A nanohybrid system for taste masking of sildenafil.Evaluation of octyl p-methoxycinnamate included in liposomes and cyclodextrins in anti-solar preparations: preparations, characterizations and in vitro penetration studiesAccelerated in-vitro release testing methods for extended-release parenteral dosage forms.Injectable PAMAM dendrimer-PEG hydrogels for the treatment of genital infections: formulation and in vitro and in vivo evaluationTaste Masking of Griseofulvin and Caffeine Anhydrous Using Kleptose Linecaps DE17 by Hot Melt Extrusion.Comparative Studies on the Dissolution Profiles of Oral Ibuprofen Suspension and Commercial Tablets using Biopharmaceutical Classification System CriteriaEvaluation of alternative strategies to optimize ketorolac transdermal delivery.Role of in vitro release models in formulation development and quality control of parenteral depots.Advances in orodispersible films for drug delivery.Novel formulation and drug delivery strategies for the treatment of pediatric poverty-related diseases.In-vitro dissolution methods for controlled release parenterals and their applicability to drug-eluting stent testing.Microneedle characterisation: the need for universal acceptance criteria and GMP specifications when moving towards commercialisation.Recent advances in testing of microsphere drug delivery systems.Nanostructured lipid carriers (NLC) for the delivery of natural molecules with antimicrobial activity: production, characterisation and in vitro studies.A Comparative Study of Transmembrane Diffusion and Permeation of Ibuprofen across Synthetic Membranes Using Franz Diffusion Cells.Development and characterization of repellent formulations based on nanostructured hydrogels.Effect of new curcumin-containing nanostructured lipid dispersions on human keratinocytes proliferative responses.A novel dissolution media for testing drug release from a nanostructured polysaccharide-based colon specific drug delivery system: an approach to alternative colon media.A short term quality control tool for biodegradable microspheres.Dissolution studies of poorly soluble drug nanosuspensions in non-sink conditions.Influence of unmodified and β-glycerophosphate cross-linked chitosan on anti-Candida activity of clotrimazole in semi-solid delivery systems.Development and validation of a discriminative dissolution test for nimesulide suspensions.Physicochemical performances of indomethacin in cholesteryl cetyl carbonate liquid crystal as a transdermal dosageDissolution testing of sublingual tablets: a novel in vitro method.Development of a peptide-containing chewing gum as a sustained release antiplaque antimicrobial delivery system.A model-dependent approach to correlate accelerated with real-time release from biodegradable microspheres.Comparison of three dissolution apparatuses for testing calcium phosphate pellets used as ibuprofen delivery systems.Validation of a static Franz diffusion cell system for in vitro permeation studies.In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen.Design, Development, and Optimization of Dexibuprofen Microemulsion Based Transdermal Reservoir Patches for Controlled Drug Delivery.Development of biodegradable drug releasing polymeric cardiovascular stents and in vitro evaluation.In-vitro and in-vivo evaluation of oligoethylene esters as dermal prodrugs of 18beta-glycyrrhetic acid.Monoolein aqueous dispersions as a delivery system for quercetin.In vitro–in vivo correlation from lactide-co-glycolide polymeric dosage forms.Carbon nanotube membranes to predict skin permeability of compounds.
P2860
Q30699630-34A862BF-DC3D-4C7F-B270-243FEAF52C5DQ34373809-7843F0C2-1B36-40A1-A1CD-8A64DB1613C0Q34570631-D29C9607-31D1-4A76-8A6B-1F0C391EDA50Q35176894-7BC3BB4B-2F5F-4CFA-B9EC-3AB2B708AE07Q35208156-23384FB2-5028-4477-A271-B8764C1ED68DQ35972590-781A035C-6209-4044-9627-5F4D5EF69382Q36079938-E8AA1B03-F262-4020-8299-0BAB87A217F0Q36129913-6E524675-48A0-42DD-8545-9FAFA2D49253Q36566183-096C0275-22C4-4DDD-9ED0-D601C095CB8CQ36614779-65610532-0538-400C-9FF8-E316DBD33287Q36779080-933F675D-24AB-4057-9EB2-73265DEDFCF0Q37360791-F6BC7615-08B7-4575-A92A-EBDDDC80DBEBQ37639309-7C4468F3-5F5F-403E-8B09-E0A997A11766Q37834030-0625DAB6-3374-4B49-90FA-2E4A37B4B346Q37976848-A4E6AB9B-70CA-4ED5-8933-5614889044B2Q38017707-E772F94F-E187-410F-AAC2-A72220BFB9BEQ38506865-820765AA-2CEE-4728-ACCD-745C7364BC9DQ38717509-8D8AAD25-BC65-43D6-B30E-7EB0B95A421AQ38720825-530B2B21-08FC-4A67-B219-818B81C131CFQ38753467-A79A9927-37FF-4DE1-AC90-19EBA7880758Q38754257-3DCE91BB-CE45-4B83-A892-80ACFD66473DQ38895315-CE8EC1DB-750C-4E04-95D8-32933A158CC3Q39344860-D41A1B4E-EE07-4CA3-B96A-D164D9DE42FBQ40027648-B88ACD04-9F1C-411E-BB35-E2AD3AEF56B5Q41123739-54A4BCC6-6D12-49E7-B8C8-BB3FC3404776Q41720282-5AD5AE8A-2525-4351-AC6F-F231CF78234DQ41982851-E27FA1A8-036A-40FD-92B2-B0B5F86A42E4Q41988331-207FDA22-A2DA-4138-9B88-D9D05EF82EB2Q41988606-F5F646EF-5EC9-4229-AA11-E611A42BDEB4Q41989952-10EAEE1F-F26D-46F4-810A-A3FB14B2DA6BQ41990221-C0CBC4F1-6ADA-48BE-A6A5-01E687803B13Q42205504-C7B1C5B3-3CE8-4E4A-A034-A8EEAEA7ECE2Q42380437-ECFB3F07-5E2B-4A12-81D2-BE401024727BQ42442565-F79F38B3-CCE3-447F-B418-775929C079F2Q42705880-DC1BC767-E39D-4245-9D7C-01F2CD9BF5A8Q46030040-11895FB1-5C21-4B29-8138-AD7416C8C56FQ46990173-3F143160-9722-452F-AB8D-9C1EB7B5BA2BQ48173029-79EFAC0A-486A-4E3B-B3D3-B008D8FB23B6Q49707213-3D8AF353-AB05-4B3A-9821-DE32D8AB6A1CQ50599367-5446C57F-3139-4F57-8D1E-929203845621
P2860
FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2003
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
FIP/AAPS guidelines to dissolu ...... of novel/special dosage forms.
@en
FIP/AAPS guidelines to dissolu ...... of novel/special dosage forms.
@nl
type
label
FIP/AAPS guidelines to dissolu ...... of novel/special dosage forms.
@en
FIP/AAPS guidelines to dissolu ...... of novel/special dosage forms.
@nl
prefLabel
FIP/AAPS guidelines to dissolu ...... of novel/special dosage forms.
@en
FIP/AAPS guidelines to dissolu ...... of novel/special dosage forms.
@nl
P2093
P2860
P356
P1433
P1476
FIP/AAPS guidelines to dissolu ...... of novel/special dosage forms.
@en
P2093
Cynthia K Brown
Jennifer Dressman
Martin Siewert
Vinod P Shah
P2860
P2888
P356
10.1208/PT040107
P407
P577
2003-01-01T00:00:00Z